Loading
A phase 2 trial of SYS6010 in head and neck squamous cell carcinoma, run by CSPC Megalith Biopharmaceutical Co.,Ltd., now recruiting.
SYS6010 Combined With Enlonstobart In Recurrent Or Metastatic Head And Neck Squamous Cell Carcinoma is a phase 2 interventional study registered as NCT07254585 by CSPC Megalith Biopharmaceutical Co.,Ltd., with 70 participants planned, started 2025-12-18 and due to reach its primary completion in 2026-06-30. Interventions recorded: SYS6010 injection, Enlonstobart injection. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares SYS6010, CSPC Pharmaceutical Group.
Shares SYS6010, CSPC Pharmaceutical Group.
Shares SYS6010, CSPC Pharmaceutical Group.
Shares SYS6010, CSPC Pharmaceutical Group.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares Recurrent or metastatic head and neck squamous cell carcinoma, Head and neck squamous cell carcinoma.
Shares SYS6010, CSPC Pharmaceutical Group.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/